Table 1.
Year | Total OUD person- months | Injectable naltrexone | Oral naltrexone | Sublingual or oromucosal buprenorphine/naloxone | Sublingual buprenorphine | Transdermal buprenorphine* | Total Prescribed months /total OUD person months | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescribed mo. | % of total | Prescribed mo. | % of total | Prescribed mo. | % of total | Prescribed mo. | % of total | Prescribed mo. | % of total | |||
2010 | 411,936 | 195 | 0.2% | 1,435 | 1.4% | 95,299 | 92.6% | 5,966 | 5.8% | 0 | 0.0% | 25.0% (102,895/411,936) |
2011 | 875,105 | 637 | 0.3% | 2,929 | 1.6% | 169,075 | 90.7% | 12,021 | 6.4% | 1,805 | 1.0% | 21.3% (186,467/875,105) |
2012 | 1,286,954 | 1,425 | 0.6% | 4,041 | 1.6% | 219,655 | 89.3% | 17,392 | 7.1% | 3,399 | 1.4% | 19.1% 245,912/1,286,954) |
2013 | 1,315,446 | 2,243 | 0.9% | 4,626 | 1.9% | 208,195 | 87.6% | 18,612 | 7.8% | 3,867 | 1.6% | 18.1% (237,543/1,315,446) |
2014 | 1,739,560 | 2,830 | 1.0% | 6,144 | 2.2% | 239,632 | 86.0% | 24,423 | 8.8% | 5,742 | 2.1% | 16.0% (278,771/1,739,560) |
OUD = opioid use disorder
Transdermal mono buprenorphine is FDA-approved for the treatment of chronic pain, not opioid use disorder.